Cancer research may be one of the most exciting industries known to mankind. This field of work hosts some of the brightest of minds, and it produces plenty of up-and-coming medications for fighting cancer. Seattle Genetics is a top contender of the cancer-research community thanks to its brilliance, its hard work, and its dedication. Dr. Clay Siegall is the headman in charge of this gigantic ship, and he is ushering-in a new era of targeted-cancer therapies. Over the past five years, Seattle Genetics stock has tripled, it has generated over $400 million in revenue for the 2016 fiscal-year, and it is now worth an estimated $10 billion. What more can you say?
The company’s top-selling drug, ADCETRIS, has generated upward $350 million since it became FDA-approved in 2011. This phenomenal drug is in a class of its own thanks to its advanced actions in fighting cancer. ADCETRIS affectively targets cancer cells within the body by attaching itself to the cancer cells. The antibodies of this drug delivers its payload directly into cancer cells without harming any of the good cells in the body. You won’t find a more advanced drug than this. ADCETRIS affectively treats Hodgkin Lymphoma. Dr. Siegall, CEO and president of Seattle Genetics, was able to acquire multiple licensing deals with major pharmaceutical companies like Bayer, Genentech and Pfizer. Thanks to these wonderful deals, ADCETRIS can now be used in over 60 countries.
The growth of Seattle Genetics comes from many contributions, but Dr. Siegall is definitely on the top of the list. To take the company even farther, Dr. Siegall has opened an office in Switzerland for handling the company’s international-marketing rights. No longer will the company have to raise much-needed funds for producing newer drugs because it will now be able to control its own destiny.